Ph− myeloproliferative neoplasms and the related risk factors for stroke occurrence: results from a registry of patients treated with Anagrelide

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F21%3A00013027" target="_blank" >RIV/00023736:_____/21:00013027 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11150/21:10419969 RIV/00216208:11110/21:10419969 RIV/65269705:_____/21:00075873 RIV/00179906:_____/21:10419969 RIV/00216224:14110/21:00120658
Result on the web
<a href="https://doi.org/10.1007/s11239-020-02175-8" target="_blank" >https://doi.org/10.1007/s11239-020-02175-8</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s11239-020-02175-8" target="_blank" >10.1007/s11239-020-02175-8</a>

Result language
angličtina
Original language name
Ph− myeloproliferative neoplasms and the related risk factors for stroke occurrence: results from a registry of patients treated with Anagrelide
Original language description
Arterial thrombosis is a common complication in patients with Ph− myeloproliferative neoplasms (MPN). We searched for the risk factors of stroke in MPN patients from anagrelide registry. We analyzed the potential risk factors triggering a stroke/TIA event in 249 MPN patients with previous stroke (n = 168) or Transient Ischemic Attack (TIA) (n = 140), and in 1,193 MPN control subjects (without clinical history of thrombosis).
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)